Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$78.5M+90.4%
Insmed logo
InsmedINSM
$29.51M+1.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-$538.8M+20.8%
Roivant Sciences logo
Roivant SciencesROIV
——
Gilead Sciences logo
Gilead SciencesGILD
——
Biogen logo
BiogenBIIB
——

Other financials

Income statement

See full
Revenue-—
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0×0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
Summit Therapeutics (SMMT) reported cash provided by (used in) financing activity, including discontinued operation of $3.8M in Q1 2026.
How has Summit Therapeutics's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Summit Therapeutics's cash provided by (used in) financing activity, including discontinued operation decreased by 50.5% year-over-year, from $7.68M to $3.8M.
What is the long-term trend for Summit Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), Summit Therapeutics's cash provided by (used in) financing activity, including discontinued operation has grown at a 67.8% compound annual growth rate (CAGR), from $77.92M to $617.53M.